The role of amifostine as a radioprotector

ONCOLOGY

Volumn 15, Issue 10, 2001, Pages 1349-1354

  Wasserman, Todd H ^a   Brizel, David M ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; RADIOPROTECTIVE AGENT;

HUMAN; MULTIMODALITY CANCER THERAPY; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RADIATION INJURY; RADIATION RESPONSE; RADIOTHERAPY; REVIEW;

AMIFOSTINE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY;

EID: 0035491973     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Cox JD, Azarnia N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543-1555, 1990.
2. Horiot JC, Le Fur R, N'Guyen T, et al: Hyperfractionation vs conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiother Oncol 25:231-241, 1992.
3. Saunders MI, Dische S, Barrett A, et al: Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: An interim report. Brit J Cancer 73:1455-1462, 1996.
4. Purdy JA: Advances in three-dimensional treatment planning and conformal dose delivery. Semin Oncol 24:655-671, 1997.
5. Wasserman TH, Simpson JR, Drzymala RE, et al: Stereotactic Irradiation (Radiosurgery), in Perez CA, Brady LW (eds): Principles and Practice of Radiation Oncology, pp 387-404. Philadelphia, Lippincott-Raven, 1997.
6. Milas L, Murray D, Brock WA, et al: Radioprotectors in tumor radiotherapy: Factors and settings determining therapeutic ratio. Pharmacol Ther 39:179-187, 1988.
7. van Leeuwen FE, Klokman WJ, van't Veer MB, et al: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18:487-497, 2000.
8. Capizzi RL: Clinical status and optimal use of amifostine. Oncology 13(1):47-59; discussion 63, 67, 1999 Jan.
9. Grdina D, Sigdestad C: Radiation protectors: The unexpected benefit. Drug Metab Rev 20:13-42, 1989.
10. Kligerman MM, Turrisi AT, Urtasun RC, et al: Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys 14:1119, 1988.